Kymab

Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

https://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/

Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bn

https://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/

Record number of health firms feature in UK top 100 private tech list

https://pharmaphorum.com/news/babylon-among/

Kymab signs immuno-oncology deal for bi-specific antibodies

https://pharmaphorum.com/news/kymab-signs-immuno-oncology-deal-bi-specific-antibodies/

UK’s Kymab could help develop HIV vaccine

https://pharmaphorum.com/news/uks-kymab-help-develop-hiv-vaccine/

Will the UK ever produce a world-class biotech company?

https://pharmaphorum.com/views-and-analysis/will-uk-ever-produce-world-class-biotech-company-2/

Close in 10 seconds

Pharmaphorum.com

Search